Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 4, 2012, Pages 399-407

  Altintas, Isil ^a   Kok, Robbert Jan ^a   Schiffelers, Raymond M ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibody; Drug delivery systems; Epidermal growth factor receptor; Nanobody

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BETA LAPACHONE; CANERTINIB; CETUXIMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GOLD NANOPARTICLE; LAPATINIB; MONOCLONAL ANTIBODY; NANOPARTICLE; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TRASTUZUMAB;

ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN RECOGNITION; BREAST CANCER; COLON CARCINOMA; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; LIGAND BINDING; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; RASH; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; NANOPARTICLES; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856282034     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.10.015     Document Type: Conference Paper

References (67)

1. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 2009 5737 5750
2. M.G. Anhorn, S. Wagner, J. Kreuter, K. Langer, and H. von Briesen Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles Bioconjug. Chem. 19 2008 2321 2331
3. I. Astsaturov, R.B. Cohen, and P. Harari EGFR-targeting monoclonal antibodies in head and neck cancer Curr. Cancer Drug Targets 7 2007 650 665 (Pubitemid 350074968)
4. P.A. Barthelemy, H. Raab, B.A. Appleton, C.J. Bond, P. Wu, C. Wiesmann, and S.S. Sidhu Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains J. Biol. Chem. 283 2008 3639 3654
5. S. Basu, P. Chaudhuri, and S. Sengupta Targeting oncogenic signaling pathways by exploiting nanotechnology Cell Cycle 8 2009 3480 3487
6. A. Bell, Z.J. Wang, M. Arbabi-Ghahroudi, T.A. Chang, Y. Durocher, U. Trojahn, J. Baardsnes, M.L. Jaramillo, S. Li, T.N. Baral, M. O'Connor-McCourt, R. MacKenzie, and J. Zhang Differential tumor-targeting abilities of three single-domain antibody formats Cancer Lett. 289 2010 81 90
7. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
8. P. Chames, M. Van Regenmortel, E. Weiss, and D. Baty Therapeutic antibodies: successes, limitations and hopes for the future Br. J. Pharmacol. 157 2009 220 233
9. F.L. Chen, W. Xia, and N.L. Spector Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors Clin. Cancer Res. 14 2008 6730 6734
10. A. Cirstoiu-Hapca, F. Buchegger, L. Bossy, M. Kosinski, R. Gurny, and F. Delie Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells Eur. J. Pharm. Sci. 38 2009 230 237
11. V. Cortez-Retamozo, N. Backmann, P.D. Senter, U. Wernery, P. De Baetselier, S. Muyldermans, and H. Revets Efficient cancer therapy with a nanobody-based conjugate Cancer Res. 64 2004 2853 2857 (Pubitemid 38500625)
12. V. Cortez-Retamozo, M. Lauwereys, Gh.G. Hassanzadeh, M. Gobert, K. Conrath, S. Muyldermans, P. De Baetselier, and H. Revets Efficient tumor targeting by single-domain antibody fragments of camels Int. J. Cancer 98 2002 456 462 (Pubitemid 34188691)
13. P. Couvreur, and C. Vauthier Nanotechnology: intelligent design to treat complex disease Pharm. Res. 23 2006 1417 1450 (Pubitemid 43993807)
14. C.V. Dang, and G.L. Semenza Oncogenic alterations of metabolism Trends Biochem. Sci. 24 1999 68 72 (Pubitemid 29346576)
15. O. Dassonville, A. Bozec, J.L. Fischel, and G. Milano EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors: similarities and differences Crit. Rev. Oncol. 62 2007 53 61 (Pubitemid 46330798)
16. D.R. Davies, E.A. Padlan, and S. Sheriff Antibody-antigen complexes Annu. Rev. Biochem. 59 1990 439 473
17. S.S. Davis Biomédical applications of nanotechnology - implications for drug targeting and gene therapy Trends Biotechnol. 15 1997 217 224 (Pubitemid 27242747)
18. R.O. Dillman Monoclonal antibodies for targeting cancer Ann. Inter. Med. 111 1989 592
19. B. Feng, K. Tomizawa, H. Michiue, S. Miyatake, X. Han, A. Fujimura, M. Seno, M. Kirihata, and H. Matsui Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His Biomaterials 30 2009 1746 1755
20. C. Fung, and J.R. Grandis Emerging drugs to treat squamous cell carcinomas of the head and neck Expert Opin. Emerg. Drugs 15 2010 355 373
21. E.B. Gottlin, X. Guan, C. Pegram, A. Cannedy, M.J. Campa, and E.F. Patz Isolation of novel EGFR-specific VHH domains J. Biomol. Screen 14 2009 77 85
22. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448 (Pubitemid 23179389)
23. A. Harandi, A. Zaidi, A. Stocker, and D. Laber Clinical efficacy and toxicity of anti-EGFR therapy in common cancers J. Oncol. 2009 2009 567486
24. M.M. Harmsen, R.C. Ruuls, I.J. Nijman, T.A. Niewold, L.G.J. Frenken, and B. de Geus Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features Mol. Immunol. 37 2000 579 590 (Pubitemid 32052527)
25. M.M. Harmsen, C.B. Van Solt, H.P.D. Fijten, and M.C. Van Setten Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins Vaccine 23 2005 4926 4934 (Pubitemid 41242869)
26. I. Hmila, D. Saerens, R. Ben Abderrazek, C. Vincke, N. Abidi, Z. Benlasfar, J. Govaert, M. El Ayeb, B. Bouhaouala-Zahar, and S. Muyldermans A bispecific nanobody to provide full protection against lethal scorpion envenoming FASEB J. 24 2010 3479 3489
27. P. Holliger, and P.J. Hudson Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23 2005 1126 1136 (Pubitemid 41486394)
28. L. Huang, G. Lot, V. Caveliers, C. Vanhove, M. Keyaerts, P. De Baetselier, A. Bossuyt, H. Revets, and T. Lahoutte SPECT imaging with 99m Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression Mol. Imag. Biol. 10 2008 167
29. P.J. Hudson Recombinant antibody fragments Curr. Opin. Biotechnol. 9 1998 395 402 (Pubitemid 28395649)
30. U. Iqbal, H. Albaghdadi, Y. Luo, M. Arbabi, C. Desvaux, T. Veres, D. Stanimirovic, and A. Abulrob Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies Br. J. Cancer 103 2010 1606 1616
31. S. Jeong, S. Park, S.M. Yoon, J. Jung, H.N. Woo, S.L. Yi, S.Y. Song, H.J. Park, C. Kim, J.S. Lee, J.S. Lee, and E.K. Choi Systemic delivery and preclinical evaluation of Au nanoparticle containing β-lapachone for radiosensitization J. Controlled Release 139 2009 239 245
32. V. Joosten, M.S. Roelofs, N. van den Dries, T. Goosen, C.T. Verrips, C.A.M.J.J. van den Hondel, and B.C. Lokman Production of bifunctional proteins by Aspergillus awamori: Llama variable heavy chain antibody fragment (VHH) R9 coupled to Arthromyces ramosus peroxidase (ARP) J. Biotechnol. 120 2005 347 359 (Pubitemid 41627964)
33. G. Keating Panitimumab: a review of its use in metastatic colorectal cancer Drugs 70 2010 1059 1078
34. S.P. Langdon, D. Faratian, Y. Nagumo, P. Mullen, and D.J. Harrison Pertuzumab for the treatment of ovarian cancer Expert Opin. Biol. Ther. 10 2010 1113 1120
35. A.L.Z. Lee, Y. Wang, H.Y. Cheng, S. Pervaiz, and Y.Y. Yang The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles Biomaterials 30 2009 919 927
36. Y. Liu, K. Li, B. Liu, and S. Feng A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery Biomaterials 31 2010 9145 9155
37. R.J. MacFarlane, and K.A. Gelmon Lapatinib for breast cancer: a review of the current literature Expert Opin. Drug Saf. 10 2011 109 121
38. F. Marcucci, and F. Lefoulon Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress Drug Discov. Today 9 2004 219 228 (Pubitemid 38230021)
39. Q.F. Miao, X.Y. Liu, B.Y. Shang, Z.G. Ouyang, and Y.S. Zhen An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity Anticancer Drugs 2 2007 137
40. M. Michaelis, J. Bliss, S. Arnold, N. Hinsch, F. Rothweiler, H. Deubzer, O. Witt, K. Langer, H. Doerr, W. Wels, and J.J. Cinatl Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins Clin. Cancer Res. 14 2008 6531 6537
41. S. Muyldermans Single domain camel antibodies: current status Rev. Mol. Biotechnol. 74 2001 277 302 (Pubitemid 34179619)
42. S. Muyldermans, and M. Lauwereys Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies J. Mol. Recognit. 12 1999 131 140 (Pubitemid 29178088)
43. S. Oliveira, R.M. Schiffelers, J. van der Veeken, R. van der Meel, R. Vongpromek, P.M. van Bergen en Henegouwen, M.P. Paul, G. Storm, and R.C. Roovers Downregulation of EGFR by a novel multivalent nanobody-liposome platform J. Controlled Release 145 2010 165 175
44. C.R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J.S. Lau, S. Dutta, M. Muders, S. Wang, S.A. Buhrow, S.L. Safgren, M.J. Yaszemski, J.M. Reid, M.M. Ames, P. Mukherjee, and D. Mukhopadhyay Targeted delivery of Gemcitabine to pancreatic adenocarcinoma using Cetuximab as a targeting agent Cancer Res. 68 2008 1970 1978 (Pubitemid 351416584)
45. N. Rapoport Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery Prog. Polym. Sci. 32 2007 962 990 (Pubitemid 47198285)
46. L. Riechmann, and S. Muyldermans Single domain antibodies: comparison of camel VH and camelised human VH domains J. Immunol. Methods 231 1999 25 38
47. R.C. Roovers, T. Laeremans, L. Huang, S. De Taeye, A.J. Verkleij, H. Revets, H.J. de Haard, and P.M. van Bergen en Henegouwen Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies Cancer Immunol. Immunother. 56 2007 303 317 (Pubitemid 46035901)
48. A. Safavy, J. Bonner, H. Waksal, D. Buchsbaum, G. Gillespie, M. Khazaeli, R. Arani, D. Chen, M. Carpenter, and K. Raisch Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery Bioconjug. Chem. 14 2003 302 310 (Pubitemid 36348653)
49. L. Sanz, A.M. Cuesta, M. Compte, and L. Alvarez-Vallina Antibody engineering: facing new challenges in cancer therapy Acta Pharmacol. Sin. 26 2005 641 648 (Pubitemid 40806551)
50. L.S. Shahied, Y. Tang, R.K. Alpaugh, R. Somer, D. Greenspon, and L.M. Weiner Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format J. Biol. Chem. 279 2004 53907 53914 (Pubitemid 40053120)
51. K.R. Sridhar Antitumor activity of HER-2 inhibitors Cancer Lett. 227 2005 9 23
52. M. Steins, N. Reinmuth, H. Bischoff, M. Kindermann, and M. Thomas Targeting the epidermal growth factor receptor in non-small cell lung cancer Onkologie 33 2010 704 709
53. E. Stone, T. Hirama, J. Tanha, H. Tong-Sevinc, S. Li, C.R. MacKenzie, and J. Zhang The assembly of single domain antibodies into bispecific decavalent molecules J. Immunol. Methods 318 2007 88 94 (Pubitemid 46026811)
54. M. Talelli, C.J.F. Rijcken, S. Oliveira, R. van der Meel, Paul M.P. van Bergen en Henegouwen, T. Lammers, C.F. van Nostrum, G. Storm, and W.E. Hennink Nanobody - Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting J. Controlled Release 151 2011 183 192
55. B.M. Tijink, T. Laeremans, M. Budde, M. Stigter-vanWalsum, T. Dreier, H.J. de Haard, C.R. Leemans, and G.A. van Dongen Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology Mol. Cancer Ther. 7 2008 2288 2297
56. P. Traxler Tyrosine kinases as targets in cancer therapy-successes and failures Expert Opin. Ther. Targets 7 2003 215 234 (Pubitemid 36512022)
57. R. van der Linden, B. de Geus, W. Stok, W. Bos, D. van Wassenaar, T. Verrips, and L. Frenken Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama J. Immunol. Methods 240 2000 185 195 (Pubitemid 30347413)
58. I. Vaneycken, J. Govaert, C. Vincke, V. Caveliers, T. Lahoutte, P. De Baetselier, G. Raes, A. Bossuyt, S. Muyldermans, and N. Devoogdt In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/Micro-CT J. Nucl. Med. 51 2010 1099 1106
59. J. Vega, S. Ke, Z. Fan, S. Wallace, C. Charsangavej, and C. Li Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(l-glutamic acid) through a polyethylene glycol spacer Pharm. Res. 20 2003 826 832 (Pubitemid 36515318)
60. C. Vincke, R. Loris, D. Saerens, S. Martinez-Rodriguez, S. Muyldermans, and K. Conrath General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold J. Biol. Chem. 284 2009 3273 3284
61. A. Vuchelen, E. O'Day, E. De Genst, E. Pardon, L. Wyns, M. Dumoulin, C.M. Dobson, J. Christodoulou, and S.T. Hsu (1)H, (13)C and (15)N assignments of a camelid nanobody directed against human alpha-synuclein Biomol. NMR Assign. 3 2009 231 233
62. W. Wels, M. Biburger, T. Muller, B. Dalken, U. Giesubel, T. Tonn, and C. Uherek Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors Cancer Immunol. Immunother. 53 2004 217 226 (Pubitemid 38328044)
63. J. Wesolowski, V. Alzogaray, J. Reyelt, M. Unger, K. Juarez, M. Urrutia, A. Cauerhff, W. Danquah, B. Rissiek, F. Scheuplein, N. Schwarz, S. Adriouch, O. Boyer, M. Seman, A. Licea, D.V. Serreze, F.A. Goldbaum, F. Haag, and F. Koch-Nolte Single domain antibodies: promising experimental and therapeutic tools in infection and immunity Med. Microbiol. Immunol. 198 2009 157 174
64. W. Wolfson Ablynx makes nanobodies from Llama bodies Chem. Biol. 13 2006 1243 1244 (Pubitemid 44918391)
65. K. Wong Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors Lung Cancer 60 2008 S10 S18
66. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137 (Pubitemid 33674041)
67. J. Zhang, Q. Li, T. Nguyen, T. Tremblay, E. Stone, R. To, J. Kelly, and C. Roger MacKenzie A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents J. Mol. Biol. 341 2004 161 169 (Pubitemid 39090642)